Effect of AN-PEP Enzyme on Gluten Digestion - Full Text View

Purpose

The aim is to demonstrate how fast and to what extent AN-PEP can degrade gluten in vivo in the stomach and how much gluten enters the small intestine. A second question is whether the caloric density of a meal can influence the efficacy of AN-PEP breakdown.

Condition	Intervention
Gluten Digestion	Dietary Supplement: AN-PEP


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment
Official Title:	Effect of AN-PEP Enzyme on Gastrointestinal Breakdown of Gluten

Further study details as provided by DSM Food Specialties:

Primary Outcome Measures:

Effect of AN-PEP with a low or high caloric meal on gluten degradation in the duodenum [ Time Frame: 0-240 min ] [ Designated as safety issue: No ]
Difference in gluten (volume x concentration) x time between AN-PEP and placebo with a low or high caloric meal in the duodenum

Secondary Outcome Measures:

Effect of AN-PEP with a low or high caloric meal on gluten degradation in the stomach [ Time Frame: 0-240 min ] [ Designated as safety issue: No ]
Difference in gluten concentration x time between AN-PEP and placebo with a low or high caloric meal in the stomach
Effect of meal caloric density on gastric emptying [ Time Frame: 0-240 min ] [ Designated as safety issue: No ]
Difference in gastric half emptying time by 13CO2:12CO2 in breath between the high and low caloric meals
Effect of AN-PEP and meal caloric density on gastric and duodenal pH [ Time Frame: 0-240 min ] [ Designated as safety issue: No ]
Change in gastric and duodenal pH over time
Effect of caloric density on AN-PEP-mediated gluten degradation in the duodenum [ Time Frame: 0-240 min ] [ Designated as safety issue: No ]
Difference in gluten (concentration) x time between AN-PEP with a high vs low caloric meal in the duodenum
Effect of caloric density on AN-PEP-mediated gluten degradation in the stomach [ Time Frame: 0-240 min ] [ Designated as safety issue: No ]
Difference in gluten concentration x time between AN-PEP with a high vs low caloric meal in the stomach


Enrollment:	12
Study Start Date:	April 2011
Study Completion Date:	May 2012
Primary Completion Date:	May 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: AN-PEP with low caloric meal	Dietary Supplement: AN-PEP Endoprotease enzyme (AN-PEP) Other Name: Aspergillus Niger Prolyl EndoProtease enzyme (AN-PEP)
Active Comparator: AN-PEP with high caloric meal	Dietary Supplement: AN-PEP Endoprotease enzyme (AN-PEP) Other Name: Aspergillus Niger Prolyl EndoProtease enzyme (AN-PEP)
Placebo Comparator: Placebo with low caloric meal	Dietary Supplement: AN-PEP Endoprotease enzyme (AN-PEP) Other Name: Aspergillus Niger Prolyl EndoProtease enzyme (AN-PEP)
Placebo Comparator: Placebo with high caloric meal	Dietary Supplement: AN-PEP Endoprotease enzyme (AN-PEP) Other Name: Aspergillus Niger Prolyl EndoProtease enzyme (AN-PEP)

Detailed Description:

In this trial, the effect of AN-PEP enzyme on gastrointestinal breakdown of gluten will be investigated in healthy subjects. In addition, it will be assessed if meal calories can affect the efficacy of AN-PEP. Subjects receive intragastrically, either AN-PEP or placebo, with either a high or a low caloric meal in a double-blind, randomized, placebo-controlled, cross-over fashion. Gastrointestinal fluid will be sampled to measure breakdown of gluten.

Eligibility


Ages Eligible for Study:	18 Years to 44 Years (Adult)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Male/female
Age ≥ 18 years but < 45 years
Hormonal contraceptive treatment
Subject has read and understood the information provided on the study and given written informed consent

Exclusion Criteria:

Any medical condition or laboratory test result that in the opinion of the investigators may interfere with the study and may jeopardise the health status of the participant
pregnancy or lactation
women not treated with hormonal contraceptive treatment

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01335503

Locations


Netherlands
Maastricht University
Maastricht, Netherlands

Sponsors and Collaborators

DSM Food Specialties

Investigators


Principal Investigator:	Ad Masclee, Prof Dr	Maastricht University Medical Center

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Bartholomé R, Salden B, Vrolijk MF, Troost FJ, Masclee A, Bast A, Haenen GR. Paracetamol as a Post Prandial Marker for Gastric Emptying, A Food-Drug Interaction on Absorption. PLoS One. 2015 Sep 9;10(9):e0136618. doi: 10.1371/journal.pone.0136618. eCollection 2015.

Salden BN, Monserrat V, Troost FJ, Bruins MJ, Edens L, Bartholomé R, Haenen GR, Winkens B, Koning F, Masclee AA. Randomised clinical study: Aspergillus niger-derived enzyme digests gluten in the stomach of healthy volunteers. Aliment Pharmacol Ther. 2015 Aug;42(3):273-85. doi: 10.1111/apt.13266. Epub 2015 Jun 4.


Responsible Party:	DSM Food Specialties
ClinicalTrials.gov Identifier:	NCT01335503 History of Changes
Other Study ID Numbers:	AN-PEP-02
Study First Received:	April 12, 2011
Last Updated:	August 12, 2013
Health Authority:	Netherlands: Medical Ethics Review Committee (METC)

Keywords provided by DSM Food Specialties:


gluten

ClinicalTrials.gov processed this record on September 23, 2016